Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg
Abstract Until relatively recently, a diagnosis of probable Alzheimer’s disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold standard for disease confirmation. This is in sharp contrast to other areas of medi...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-02-01
|
| Series: | Alzheimer’s Research & Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13195-020-00586-6 |
| _version_ | 1818985007215017984 |
|---|---|
| author | Pawel Obrocki Ayesha Khatun Deborah Ness Konstantin Senkevich Jörg Hanrieder Federica Capraro Niklas Mattsson Ulf Andreasson Erik Portelius Nicholas J. Ashton Kaj Blennow Michael Schöll Ross W. Paterson Jonathan M. Schott Henrik Zetterberg |
| author_facet | Pawel Obrocki Ayesha Khatun Deborah Ness Konstantin Senkevich Jörg Hanrieder Federica Capraro Niklas Mattsson Ulf Andreasson Erik Portelius Nicholas J. Ashton Kaj Blennow Michael Schöll Ross W. Paterson Jonathan M. Schott Henrik Zetterberg |
| author_sort | Pawel Obrocki |
| collection | DOAJ |
| description | Abstract Until relatively recently, a diagnosis of probable Alzheimer’s disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold standard for disease confirmation. This is in sharp contrast to other areas of medicine, where fluid biomarkers, such as troponin levels in myocardial infarction, form an integral part of the diagnostic and treatment criteria. There is a pressing need for such quantifiable and easily accessible tools in neurodegenerative diseases. In this paper, based on lectures given at the 2019 Biomarkers in Neurodegenerative Diseases Course, we provide an overview of a range of cerebrospinal fluid (CSF) and blood biomarkers in neurodegenerative disorders, including the ‘core’ AD biomarkers amyloid β (Aβ) and tau, as well as other disease-specific and general markers of neuroaxonal injury. We then highlight the main challenges in the field, and how those could be overcome with the aid of new methodological advances, such as assay automation, mass spectrometry and ultrasensitive immunoassays. As we hopefully move towards an era of disease-modifying treatments, reliable biomarkers will be essential to increase diagnostic accuracy, allow for earlier diagnosis, better participant selection and disease activity and treatment effect monitoring. |
| first_indexed | 2024-12-20T18:28:03Z |
| format | Article |
| id | doaj.art-71d72066c72a4b1181d4f1c6de9658ce |
| institution | Directory Open Access Journal |
| issn | 1758-9193 |
| language | English |
| last_indexed | 2024-12-20T18:28:03Z |
| publishDate | 2020-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Alzheimer’s Research & Therapy |
| spelling | doaj.art-71d72066c72a4b1181d4f1c6de9658ce2022-12-21T19:30:05ZengBMCAlzheimer’s Research & Therapy1758-91932020-02-0112111010.1186/s13195-020-00586-6Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of GothenburgPawel Obrocki0Ayesha Khatun1Deborah Ness2Konstantin Senkevich3Jörg Hanrieder4Federica Capraro5Niklas Mattsson6Ulf Andreasson7Erik Portelius8Nicholas J. Ashton9Kaj Blennow10Michael Schöll11Ross W. Paterson12Jonathan M. Schott13Henrik Zetterberg14Department of Medicine, St Mary’s Hospital, Imperial College Healthcare NHS TrustDementia Research Centre, Department of Neurodegeneration, UCL Institute of NeurologyDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonFirst Pavlov State Medical University of St. PetersburgDepartment of Molecular Neuroscience, UCL Institute of NeurologyThe Francis Crick InstituteClinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund UniversityDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of GothenburgDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of GothenburgDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of GothenburgDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of GothenburgDementia Research Centre, Department of Neurodegeneration, UCL Institute of NeurologyDementia Research Centre, Department of Neurodegeneration, UCL Institute of NeurologyDementia Research Centre, Department of Neurodegeneration, UCL Institute of NeurologyDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of GothenburgAbstract Until relatively recently, a diagnosis of probable Alzheimer’s disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold standard for disease confirmation. This is in sharp contrast to other areas of medicine, where fluid biomarkers, such as troponin levels in myocardial infarction, form an integral part of the diagnostic and treatment criteria. There is a pressing need for such quantifiable and easily accessible tools in neurodegenerative diseases. In this paper, based on lectures given at the 2019 Biomarkers in Neurodegenerative Diseases Course, we provide an overview of a range of cerebrospinal fluid (CSF) and blood biomarkers in neurodegenerative disorders, including the ‘core’ AD biomarkers amyloid β (Aβ) and tau, as well as other disease-specific and general markers of neuroaxonal injury. We then highlight the main challenges in the field, and how those could be overcome with the aid of new methodological advances, such as assay automation, mass spectrometry and ultrasensitive immunoassays. As we hopefully move towards an era of disease-modifying treatments, reliable biomarkers will be essential to increase diagnostic accuracy, allow for earlier diagnosis, better participant selection and disease activity and treatment effect monitoring.http://link.springer.com/article/10.1186/s13195-020-00586-6BiomarkersNeurodegenerationAmyloidTauNeurofilament lightNeurogranin |
| spellingShingle | Pawel Obrocki Ayesha Khatun Deborah Ness Konstantin Senkevich Jörg Hanrieder Federica Capraro Niklas Mattsson Ulf Andreasson Erik Portelius Nicholas J. Ashton Kaj Blennow Michael Schöll Ross W. Paterson Jonathan M. Schott Henrik Zetterberg Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg Alzheimer’s Research & Therapy Biomarkers Neurodegeneration Amyloid Tau Neurofilament light Neurogranin |
| title | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg |
| title_full | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg |
| title_fullStr | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg |
| title_full_unstemmed | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg |
| title_short | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg |
| title_sort | perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course a joint phd student course at university college london and university of gothenburg |
| topic | Biomarkers Neurodegeneration Amyloid Tau Neurofilament light Neurogranin |
| url | http://link.springer.com/article/10.1186/s13195-020-00586-6 |
| work_keys_str_mv | AT pawelobrocki perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT ayeshakhatun perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT deborahness perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT konstantinsenkevich perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT jorghanrieder perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT federicacapraro perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT niklasmattsson perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT ulfandreasson perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT erikportelius perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT nicholasjashton perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT kajblennow perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT michaelscholl perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT rosswpaterson perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT jonathanmschott perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg AT henrikzetterberg perspectivesinfluidbiomarkersinneurodegenerationfromthe2019biomarkersinneurodegenerativediseasescourseajointphdstudentcourseatuniversitycollegelondonanduniversityofgothenburg |